moneyheap
INSM · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Insmed, Inc. (INSM) stock moving?
Insmed reported Q3 2026 revenue of $524.4M, above the $501.4M estimate, with BRINSUPRI at $400.1M, up 29% from Q2, driven by U.S. growth, and ARIKAYCE at $124.4M, up 9% year over year. Management raised the low end of 2026 guidance, to $1.35B-$1.4B for BRINSUPRI and $460M-$470M for ARIKAYCE, and launched BRINSUPRI in Japan. Q3 EPS of $(0.46) missed the $(0.43) estimate. The CFO, Sara Bonstein, stepped down on Oct 30 and a search is underway, a negative governance item, though the company said it was not tied to any accounting disagreement. Two experienced directors were added on Oct 20, and the FDA accepted an ARIKAYCE sNDA for MAC lung disease. Analysts followed with Buy or Outperform ratings and targets from $158 (Mizuho) to $220 (H.C. Wainwright). On the market data, the stock closed at $96.98 on Oct 28, gapped to open at $110 on Oct 29 on 11.2M shares (about 3.5x the typical 3M daily volume), and has since climbed to a $119.49 close on Nov 10. Pullbacks on Nov 3 to $104.44 and Nov 5 to $108.76 were absorbed on volume near 2.6M-6.2M shares. The rally has held above the earnings-day range, but the stock has moved about 23% in two weeks, so near-term risk of consolidation is elevated.
News behind the analysis
- Insmed Named to BioSpace 2027 Best Places to Work ListInsmed was recognized as one of the top large employers in life sciences in BioSpace's 2027 Best Places to Work list.
- H.C. Wainwright Assumes Coverage of Insmed with Buy RatingH.C. Wainwright initiated coverage of Insmed with a Buy rating and a $220 price target.
- Insmed to Present at November and December 2026 Investor ConferencesInsmed announced its participation in several investor conferences scheduled for November and December 2026.
- HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220H.C. Wainwright started Insmed at Buy with a $220 price target, the highest target among the recent analyst notes.
- Guggenheim Maintains Buy Rating on Insmed, Lowers Price Target to $201Guggenheim reiterated its Buy rating and lowered its price target to $201 from $205.
- Mizuho Adjusts Price Target on Insmed to $158 From $154Mizuho raised its price target on Insmed to $158 from $154 and kept an Outperform rating.
- Insmed Reports Third-Quarter 2026 Financial Results and Provides Business UpdateQ3 2026 total revenue was $524.4M, with BRINSUPRI at $400.1M (up 29% from Q2) and ARIKAYCE at $124.4M (up 9% year over year); 2026 BRINSUPRI and ARIKAYCE revenue guidance was raised.
- Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M EstimateQ3 earnings per share missed estimates at a loss of $0.46, while sales beat the $501.4M estimate at $524.4M.
- Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B EstInsmed raised the low end of its FY2026 sales guidance to $1.810B-$1.870B, above the $1.801B consensus estimate.
About Insmed, Inc.
Insmed is a New Jersey-based biopharmaceutical company that makes treatments for serious and rare lung diseases. It stands out for BRINSUPRI (brensocatib), the first approved drug for non-cystic fibrosis bronchiectasis, which launched in the US in 2025. Its sales have grown quickly since that launch.
How it makes money
Almost all of its revenue comes from selling two drugs. BRINSUPRI, used for bronchiectasis, is now the largest; in late October 2026 the company guided to roughly $1.35–1.4 billion in BRINSUPRI sales for 2026. ARIKAYCE, an inhaled antibiotic for a hard-to-treat lung infection called MAC (a type of NTM lung disease), is guided at about $450–470 million for 2026. Revenue in Q3 2026 was about $524 million. The company still loses money because it spends heavily on research and on launching its products. It says it expects to become cash-flow positive in 2027.
What usually moves INSM
- BRINSUPRI launch sales vs. guidance
- Clinical trial readouts (brensocatib in new diseases, ARIKAYCE label expansion)
- Pipeline progress for TPIP in pulmonary hypertension
- Cash burn and path to profitability
- Competition in bronchiectasis and rare lung disease